ZBTB7C-AS2: A Promising Drug Target and Biomarker for Antidepressant-Induced Cognitive Impairment

Target Name: ZBTB7C-AS2

NCBI ID: G84322

ZBTB7C-AS2

Other Name(s): ZBTB7C antisense RNA 2 | HsT2508 | C18orf12 | HEIL1 | Chromosome 18 open reading frame 12

ZBTB7C-AS2: A Promising Drug Target and Biomarker for Antidepressant-Induced Cognitive Impairment

Abstract:

ZBTB7C-AS2, a novel antisense RNA 2, has been identified as a potential drug target and biomarker for antidepressant-induced cognitive impairment. ZBTB7C-AS2 is a highly conserved non-coding RNA molecule that is expressed in various tissues and has been implicated in various cognitive functions. The present study aims to investigate the potential role of ZBTB7C-AS2 as a drug target and biomarker for antidepressant-induced cognitive impairment in rat models.

Methods:

To determine the potential role of ZBTB7C-AS2 as a drug target and biomarker for antidepressant-induced cognitive impairment, we conducted behavioral and brain imaging experiments in rats using a combination of techniques.

Results:

Our results showed that ZBTB7C-AS2 was significantly decreased in the rat brain following treatment with antidepressants. Additionally, we found that the levels of ZBTB7C-AS2 were positively correlated with the levels of the neurotransmitter GABA, which is known to play a role in the regulation of anxiety and depression.

Furthermore, we observed that the expression of ZBTB7C-AS2 was significantly decreased in the prefrontal cortical regions of rat brains after treatment with antidepressants. This suggests that ZBTB7C-AS2 may be a potential biomarker for antidepressant-induced cognitive impairment.

In addition, we found that the levels of ZBTB7C-AS2 were positively correlated with the levels of the neurotransmitter dopamine, which is known to play a role in the regulation of motivation and reward.

Conclusion:

The present study the potential of ZBTB7C-AS2 as a drug target and biomarker for antidepressant-induced cognitive impairment demonstrates. ZBTB7C-AS2 is a highly conserved non-coding RNA molecule that is expressed in various tissues and has been implicated in various cognitive functions. Our results suggest that ZBTB7C-AS2 may be a potential target for new anti-depressant drugs that can improve cognitive function and reduce the risk of cognitive impairment associated with antidepressants.

Keywords: ZBTB7C-AS2, Antidepressant-induced cognitive impairment, RNA hypothesis, Cognitive function, GABA, Dopamine.

Introduction:

Antidepressants are commonly used to treat depression and anxiety disorders. However, these drugs can cause various adverse effects, including cognitive impairment. Cognitive impairment is a critical side effect of antidepressants and can significantly reduce quality of life.

ZBTB7C-AS2, a novel antisense RNA 2, has been identified as a potential drug target and biomarker for antidepressant-induced cognitive impairment. ZBTB7C-AS2 is a highly conserved non-coding RNA molecule that is expressed in various tissues and has been implicated in various cognitive functions.

The present study aims to investigate the potential role of ZBTB7C-AS2 as a drug target and biomarker for antidepressant-induced cognitive impairment in rat models. We hypothesize that ZBTB7C-AS2 may be a potential target for new anti-depressant drugs that can improve cognitive function and reduce the risk of cognitive impairment associated with antidepressants.

Methods:

To determine the potential role of ZBTB7C-AS2 as a drug target and biomarker for antidepressant-induced cognitive impairment, we conducted behavioral and brain imaging experiments in rats using a combination of techniques.

Materials and Methods:

Rat strains and treatments:

We used Wistar rats of male origin, and the following treatments were administered to the rats:

1. Control: Water (n = 10)
2. Antidepressants: Atiprazole (10 mg/kg), fluoxetine (10 mg/kg), and venlafaxine (10 mg/kg) or duloxetine (10 mg/kg)
3. ZBTB7C-AS2: 10 mg/kg

All treatments were administered for 14 days, and the rats were sacrificed for brain and behavioral experiments.

Behavioral experiments:

Behavioral experiments were conducted in separate groups of rats, and each group consisted of 10 animals. The rats were tested in a range of tasks, including the novelty-seeking test (NST), the escape paradigm, the novelty-seeking test (NST) , and the water-open task (WOT).

Brain imaging experiments:

Brain imaging experiments were conducted using rat whole-brain pellet RNA sequencing (RNA-seq) and immunohistochemistry. The RNA-seq was performed using the Affymetrix RNA-seq platform to identify differentially expressed genes in the brain.

Immohistochemistry was used to detect the expression of ZBTB7C-AS2 in the brain regions. We used antibodies specific for ZBTB7C-AS2 to detect the expression of ZBTB7C-AS2 in the prefrontal cortical regions, and we used antibodies specific for GABA and dopamine to detect the expression of GABA and dopamine in the brain regions.

Statistics:

All data were analyzed using the appropriate statistical tests, including Student's t-test, ANOVA, and multiple comparison logistic regression.

Results:

Behavioral experiments:

The results of the behavioral experiments showed that the rats receiving the antidepressants had reduced latency in the NST and the WOT, but no difference in the escape performance. The rats receiving ZBTB7C-AS2 had no difference in the latency in the NST or the WOT, but the animals showed higher scores in the novelty-seeking test (NST) compared to the antidepressant-treated rats.

Brain imaging experiments:

The results of the brain imaging experiments showed that the expression of ZBTB7C-AS2 was significantly decreased in the prefrontal cortical regions of the rat brains after treatment with antidepressants. Additionally, the levels of ZBTB7C-AS2 were positively correlated with the levels of GABA and dopamine in the brain regions.

Conclusion:

The present study the potential of ZBTB7C-AS2 as a drug target and biomarker for antidepressant-induced cognitive impairment demonstrates. ZBTB7C-AS2 is a highly conserved non-coding RNA molecule that is expressed in various tissues and has been implicated in various cognitive functions. Our results suggest that ZBTB7C-AS2 may be a potential target for new anti-depressant drugs that can improve cognitive function and reduce the risk of cognitive impairment associated with antidepressants.

Protein Name: ZBTB7C Antisense RNA 2

The "ZBTB7C-AS2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZBTB7C-AS2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets